focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Share News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK shareholder meetings calendar - next 7 days

Mon, 25th Oct 2021 16:03

Tuesday 26 October 
Dispersion Holdings PLCGM re share allotment
Wednesday 27 October 
Cap-XX LtdAGM
Frontier Developments PLCAGM
Hargreaves Services PLCAGM
Ideagen PLCAGM
Investment Co PLCAGM
Invinity Energy Systems PLCAGM
JPMorgan Global Growth & Income PLCAGM
Mirada PLCAGM
Pantheon International PLCAGM
Puma VCT 11 PLCGM re winding up
Springfield Properties PLCAGM
Thursday 28 October 
Brooks Macdonald Group PLCAGM
City of London Investment Trust PLCAGM
Filtronic PLCAGM
Highbridge Tactical Credit Fund LtdAGM
JD Sports Fashion PLCGM re proposed share sub-division
National Milk Records PLCAGM
South32 LtdAGM
Tirupati Graphite PLCAGM
Tirupati Graphite PLCGM re acquisition, warrants
Friday 29 October 
ADM Energy PLCAGM
Adriatic Metals PLCGM re funding package for Vares silver project
ITM Power PLCAGM
Mattioli Woods PLCAGM
MaxCyte PLCAGM
OPG Power Ventures PLCAGM
Sensyne Health PLCAGM
Monday 1 November 
Capital & Regional PLCGM re capital raising
Electra Private Equity PLCGM re Hostmore demerger
French Connection Group PLCGM re takeover by MIP Holdings
Silence Therapeutics PLCGM re cancellation of admission to trading
Vietnam Holding LtdAGM
  
Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
26 Feb 2021 17:57

LONDON TRADING UPDATES: Castings Hails Return To Pre-Covid Levels

LONDON TRADING UPDATES: Castings Hails Return To Pre-Covid Levels

Read more
26 Feb 2021 09:06

Silence to get $2m milestone payment from Mallinckrodt

(Sharecast News) - Silence Therapeutics announced on Friday that it would receive a $2m (£1.43m) milestone payment following the start of work on a third target being explored under its ongoing RNAi research collaboration with Mallinckrodt, for the treatment of complement pathway-mediated diseases.

Read more
17 Feb 2021 11:57

IN BRIEF: Silence Therapeutics Begins Dosing In SLN360 Phase 1 Trial

IN BRIEF: Silence Therapeutics Begins Dosing In SLN360 Phase 1 Trial

Read more
17 Feb 2021 08:12

Silence Therapeutics begins dosing in lipoprotein treatment trial

(Sharecast News) - Silence Therapeutics has started dosing subjects in the 'APOLLO' phase 1 clinical study of its wholly-owned lead product candidate 'SLN360', it announced on Wednesday, for the treatment of elevated lipoprotein-a (Lp(a)) levels.

Read more
5 Feb 2021 09:34

Silence Therapeutics Raises USD45 Million In Private Share Placing

Silence Therapeutics Raises USD45 Million In Private Share Placing

Read more
5 Feb 2021 09:04

Silence Therapeutics raises ?33m to support pipeline development

(Sharecast News) - Novel therapeutics developer Silence Therapeutics announced an oversubscribed private placement of 2,022,218 American depositary shares (ADSs) on Friday, raising £33m to support the development of its pipeline.

Read more
6 Jan 2021 14:27

UK EXECUTIVE CHANGE SUMMARY: Martin Gilbert Joins River & Mercantile

UK EXECUTIVE CHANGE SUMMARY: Martin Gilbert Joins River & Mercantile

Read more
6 Jan 2021 08:06

Silence Therapeutics taps Craig Tooman for CFO

(Sharecast News) - Drug discovery outfit Silence Therapeutics has named Craig Tooman as its new chief financial officer.

Read more
12 Oct 2020 22:10

UK DIRECTOR DEALINGS SUMMARY: Tesco's Simon Patterson Buys Shares

UK DIRECTOR DEALINGS SUMMARY: Tesco's Simon Patterson Buys Shares

Read more
12 Oct 2020 11:13

e-Therapeutics Names New Chief Executive; Plans To Ramp Up Research

e-Therapeutics Names New Chief Executive; Plans To Ramp Up Research

Read more
8 Oct 2020 21:16

UK EXECUTIVE CHANGE SUMMARY: Silence Wants US CFO After Nasdaq Float

UK EXECUTIVE CHANGE SUMMARY: Silence Wants US CFO After Nasdaq Float

Read more
14 Sep 2020 14:07

Silence Therapeutics Appoints Mark Rothera As CEO; Annual Loss Widens

Silence Therapeutics Appoints Mark Rothera As CEO; Annual Loss Widens

Read more
14 Sep 2020 13:14

Mark Rothera joins Silence Therapeutics as new CEO

(Sharecast News) - Drug discovery and development company Silence Therapeutics announced the appointment of Mark Rothera as its president and chief executive officer and board member on Monday, effective immediately.

Read more
8 Sep 2020 19:23

IN BRIEF: Silence Therapeutics ADSs Begin Life On Nasdaq

IN BRIEF: Silence Therapeutics ADSs Begin Life On Nasdaq

Read more
7 Sep 2020 16:03

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.